DATE	APPLICATION NO.		DATE		
PI	JP 58092445	A2	19830601	JP 1981-189145	19811127
	JP 63054412	B4	19881027		
				JP 1981-189145	19811127

L4 ANSWER 53 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Couplers (I; R1 = H, Clk, SO3H; R2 = H, Cl, OMe) possessing a combination of desirable properties and developing with agents of the p-phenylenediamine type brilliant, highly transparent dyes with absorption maximum at 645-690 nm are obtained by fusing Ph1-hydroxy-2-naphthoates with a nitroaniline, reducing the nitroamides to the amidoanilines, and condensing 2 moles of them with 1 mole of 5-octadecyloxy-isophthaloyl chloride. The color formers are used as aqueous alkaline solution or as solute dispersion.
AN 1973:117597 CAPLUS
DN 78:117597
TI Couplers for color photographic material
IN Mittag, Renate; Schindler, Wolfgang
PA VEB Filmfabrik Wolfen
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI DE 2153045	A1	19730118	DE 1971-2153045		19711025
			DD 1971-156304	A2	19710706
FR 2145143	A5	19730216	FR 1972-3293		19720201
			DD 1971-156304	A	19710706
BE 780704	A1	19720703	BE 1972-115096		19720315
			DE 1971-2153045	A	19711025A
SU 433443	T	19740625	SU 1972-1775191		19720419
			DD 1971-156304	A1	19710706

L4 ANSWER 54 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I (R = imidazolylaryl or imidazolylarylamino and the amide group is attached in the 3- or 4-position of the benzene ring) (94 compds.) were prepared Thus p-NCC6H4NHCOC6H4NH2-m was treated with p-NCC6H4NCO to give 3-(p-NCC6H4NHCO)C6H4NHCO-NHC6H4CN-p, treated with CS2 to give 3-(p-H2NCSC6H4NH-CO)C6H4NHCONHC6H4CSNH2-p, and cyclized with excess H2NCH2CH2NH2 to give II. II inhibited Mycobacterium tuberculosis at 6 mg/ml in vitro and increased the survival time of mice infected with leukemia CCNSC 1210 by 233.
AN 1972:564707 CAPLUS
DN 77:164707
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 22 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	CH 525896	A	19720731	CH 1961-525896		19610911
				CH 1969-12739	A	19610911

L4 ANSWER 55 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I, (R = imidazolylaryl imidazolylarylamino and the amido group is substituted in the 2-, 3-, or 4-position on the benzene ring) (94 compds.) were prepared by cyclizing the benzoic esters with H2N-CH2CH2NH2. Thus 5.5 g II was obtained by treating 10 g p-(p-EtO2CC6H4NHCO)2C6H4 with 50 ml H2NCH2CH2NH2. II.2HCl had in vitro tuberculostatic activity at 5.5 mg/ml and at 25 mg/kg a day it prolonged the life of Leukemia CCNSC 1210-infected mice by 330.
AN 1972:564706 CAPLUS
DN 77:164706
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 22 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	CH 525897	A	19720731	CH 1961-525897		19610911
				CH 1969-12740	A	19610911

L4 ANSWER 56 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Tuberculostatic and carcinostatic imidazolylbenzamides I (R = imidazolylaryl or imidazolylarylamino and the amido group is substituted in the 3- or 4-position of the benzene ring) and some related pyrimidyl-benzamides (105 compds.) were prepared by cyclizing the benzo-imidoic esters with an alkylenediamine. Thus 11.5 g II-diacetate was obtained by treating 15 g p-(p-EtOC(:NH)C6H4NHCO)2C6-H4 with 30 ml H2NCH2CH2NH2. At 15 mg/kg a day II pro-longed the life of Leukemia CCNSC 1210-infected mice by 270.
AN 1972:564694 CAPLUS
DN 77:164694
TI Imidazolylbenzamides
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 25 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	CH 525898	A	19720731	CH 1965-525898		19650501
				CH 1970-4234	A	19650501

L4 ANSWER 57 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Bisamidino compds. (I), effective tuberculostatic and antileukemic agents

in mice, were prepared by reaction of an alkoxy analog of I (NR1R2 replaced by OR3, where R3 = alkyl) with R2R1NH. About 63 I (n = 0, 1; R = H, Me, Et, CHMe2; R1 = H, Me, Et; R2 = H, C1-4 alkyl, (CH2)3OMe; Z = NH, CH2, or single bond) were prepared

AN 1972:461630 CAPLUS
DN 77:61630
TI Highly basic compounds for chemotherapy
IN Hirt, Rudolf; Fischer, Rudolf
PA Dr. A. Wander, A.-G.
SO Patentschrift (Switz.), 10 pp.
CODEN: SWXXAS
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 520657	A	19720331	CH 1961-520657	19610911
			CH 1965-6015 A	19610911

L4 ANSWER 58 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
AB Compds.; R1HNC(O)A(O)CNHR1 (I; R1 = alkyl, alkenyl, cycloalkyl, phenyl, phenylakyl, or phenylalkenyl; A = alkylene, phenylene, naphthylene, or biphenylene) are treated with COCl2 in the presence of amines and the reaction products treated further with R2NH2 (R2 = H or R1) to give the title compds., R2NH(R1N:)CAC(:NR1)NHR2 (II) useful as biocides. Thus, I [R1 = Et(CH2)5, A = CH2CH2SCH2CH2] in THF is mixed 30 min at 0° with dry pyridine and COCl2 in dry C6H6, the mixture kept 2 hr at 5-10°, mixed with petroleum ether, and n-hexylamine, kept 3 hr at room temperature and the product treated with saturated EtOH-(CO2H)2, to give 54% yield II.2(CO2H)2 [R1 = R2 = Me(CH2)5; A = CH2CH2SCH2CH2].
AN 1971:434674 CAPLUS
DN 75:34674
TI Substituted bisamidino compounds
IN Ookawa, Kanji; Abe, Jinnosuke; Taie, Teruo; Watanabe, Tetsuo; Fujimoto, Kentaro; Kuramoto, Masashi
PA Toyo Brewing Co., Ltd.
SO Jpn. Tokkyo Koho, 37 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 46002803	B4	19710123	JP	19670928

L4 ANSWER 59 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
AB A series of mono- and dianilido derivs. of 4-hydroxyisophthalic acid, such as 3-carbethoxy-4'-hydroxy-4-methoxybenzanilide, 5-carbomethoxy-2,4'-dihydroxybenzanilide, 3-carbethoxy-4,4'-dimethoxy-benzanilide, 5-carbomethoxy-2,4'-dimethoxybenzanilide, and 4-ethoxy-4',4''-dihydroxyisophthalanilide, were synthesized and screened for analgesic and antipyretic effects in mic e and rats, resp. The acute toxicity of 3-carbomethoxy-4,4'-dihydroxy-benzanilide, the most active compound in the series, was > 1000 mg/kg, i.p., in mice.
AN 1970:130810 CAPLUS
DN 72:130810
TI New mono- and dianilido derivatives of 4-hydroxy-isophthalic acid with

5/11/05

analgesic and antipyretic activity
AU Orzalesi, Gianni; Selleri, Renato; Caldini, Oreste; Fabrizi, P.
CS Soc. Italo-Brit. L. Manetti, H. Roberts Cie., Florence, Italy
SO Bollettino Chimico Farmaceutico (1969), 108(10), 619-31
CODEN: BCFAAI; ISSN: 0006-6648
DT Journal
LA French

L4 ANSWER 60 OF 69 CAP

10713566

L4 ANSWER 43 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB Title compound I (R = 3-pyridylmethylamino, PhCH2NH, 4-MeC6H6NH, PhNMe, dibenzylamino, 4-O2NC6H4NH, cyclohexylamino, pyrrolidino, piperidino, morpholino, N-methylpiperazinyl, 2-pyridylamino, etc.) were prepared in 33.0-93.5% yield by amidation of I (R = OH) with amines.
AN 1992:571156 CAPLUS
DN 117:171156
TI Synthesis of a platelet antiaggregant-picotamide and its analogs
AU Tong, Zeen; Chen, Wenhao; Peng, Sixun
CS Div. Med. Chem., China Pharm. Univ., Nanjing, Peop. Rep. China
SO Zhongguo Yaoke Daxue Xuebao (1992), 23(1), 1-4
CODEN: ZHYXE9; ISSN: 1000-5048
DT Journal
LA Chinese

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN

AB Novel, non-peptidic small organic compds. having an affinity for cyclophilin (CyP)-type immunophilin proteins are reported. These compds. are used for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity. Thus, 5-HOC6H3(CO2Me)2-1,3 was O-benzylated, hydrolized to the acid and treated with 3,4-Cl2C6H3NH2 to give 5-PhCH2OC6H3(CONHC6H3Cl2-3,4)2-1,3. This compound gave complete protection against cell death in L-threo-3-hydroxyaspartic acid treated spinal cord slices.

AN 2002:575044 CAPLUS

DN 137:124993

TI Trisubstituted carbocyclic cyclophilin binding compounds and their use

IN Wu, Yong-Qian; Belyakov, Sergei; Hamilton, Gregory; Limburg, David; Steiner, Joseph; Vaal, Mark; Wei, Ling; Wilkinson, Douglas

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059080	A2	20020801	WO 2002-US2538	20020125
	WO 2002059080	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-263703P	P 20010125
				US 2001-291965P	P 20010521
	CA 2435829	AA	20020801	CA 2002-2435829	20020125
				US 2001-263703P	P 20010125
				US 2001-291965P	P 20010521
				WO 2002-US2538	W 20020125
	US 2002165275	A1	20021107	US 2002-57203	20020125
	US 6656971	B2	20031202		
				US 2001-263703P	P 20010125
				US 2001-291365P	P 20010517
	EP 1360173	A2	20031112	EP 2002-706049	20020125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-263703P	P 20010125
				US 2001-291965P	P 20010521
				WO 2002-US2538	W 20020125
	JP 2004532187	T2	20041021	JP 2002-559382	20020125
				US 2001-263703P	P 20010125
				US 2001-291965P	P 20010521
				WO 2002-US2538	W 20020125
	US 2004157919	A1	20040812	US 2003-713566	20031114
				US 2002-57203	A3 20020125

OS MARPAT 137:124993

L4 ANSWER 8 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN

AB A series of arylsulfonamide and arylamide derivs. have been prepared from anisole in good yields. The structures of those compds. were confirmed by 1H-NMR and MS anal. Their activities against platelet aggregation were tested in vitro by using the Born test on rabbits.

AN 2003:561679 CAPLUS
DN 139:395672

TI Design and synthesis of new arylsulfonamide and arylamide derivatives for the platelet aggression inhibitor

AU Wang, Song Qing; Liu, Xiu Jie; Yi, Zhi Ming; Zhao, Kang
CS The College of Pharmaceuticals and Biotechnology, Tianjin University, Tianjin, 300072, Peop. Rep. China

SO Chinese Chemical Letters (2003), 14(6), 581-584
CODEN: CCLEE7; ISSN: 1001-8417
PB Chinese Chemical Society
DT Journal
LA English
OS CASREACT 139:395672

L4 ANSWER 5 OF 69 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I R=H
II R=-O-CH_2-CH_2-NH_2

AB Aryl amide oligomers with amphiphilic secondary structure were designed that attack bacteria by lysing their membranes. A variety of groups were appended to the lead compound to adjust its overall charge, hydrophobicity, and hydrophobic moment. An Arg-containing oligomer (I) was found to have good antimicrobial activity and low toxicity towards human erythrocytes. Of this series, II exhibited no toxicity.

AN 2004:209233 CAPLUS
DN 140:388528
TI Nontoxic membrane-active antimicrobial arylamide oligomers
AU Liu, Dahui; Choi, Sungwook; Chen, Bin; Doerksen, Robert J.; Clements, Dylan J.; Winkler, Jeffrey D.; Klein, Michael L.; De Grado, William F.
CS Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, 19104-6059, USA
SO Angewandte Chemie, International Edition (2004), 43(9), 1158-1162
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English

5/11/05

=>
Uploading C:\Program Files\Stnexp\Queries\10713566.str



chain nodes :
7 8 9 10 11 12 13 14 15 20 21
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7 5-11 7-8 7-9 9-10 11-12 12-13 12-14 14-15 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 7-9 12-13 12-14 20-21
exact bonds :
3-7 5-11 9-10 11-12 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

5/11/05



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 18:19:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   8384 TO ITERATE

 11.9% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       162192 TO   173168
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 18:19:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 168727 TO ITERATE

100.0% PROCESSED  168727 ITERATIONS                            156 ANSWERS
SEARCH TIME: 00.00.03

L3          156 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.33     161.54

FILE 'CAPLUS' ENTERED AT 18:19:32 ON 11 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

5/11/05

FILE COVERS 1907 - 11 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 10 May 2005 (20050510/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4           69 L3

=> s l4 and neurolog?
          5016 NEUROLOG?
         20723 NEUROL
         20723 NEUROL
                 (NEUROL)
         22866 NEUROLOG?
                 (NEUROLOG? OR NEUROL)
L5            0 L4 AND NEUROLOG?

=> s l4 and neuro?
        478804 NEURO?
L6            0 L4 AND NEURO?

=> s l4 and cns
         32968 CNS
L7            0 L4 AND CNS

=> s l4 and nerv?
        386816 NERV?
L8            1 L4 AND NERV?

=> d abs fbib hitstr

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
AB   Novel, non-peptidic small organic compds. having an affinity for cyclophilin
     (CyP)-type immunophilin proteins are reported.  These compds. are used for
     binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase
     activity.  Thus, 5-HOC6H3(CO2Me)2-1,3 was O-benzylated, hydrolized to the
     acid and treated with 3,4-Cl2C6H3NH2 to give 5-PhCH2OC6H3(CONHC6H3Cl2-
     3,4)2-1,3.  This compound gave complete protection against cell death in
     L-threo-3-hydroxyaspartic acid treated spinal cord slices.
AN   2002:575044  CAPLUS
DN   137:124993
TI   Trisubstituted carbocyclic cyclophilin binding compounds and their use
```

IN Wu, Yong-Qian; Belyakov, Sergei; Hamilton, Gregory; Limburg, David; Steiner, Joseph; Vaal, Mark; Wei, Ling; Wilkinson, Douglas
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002059080	A2	20020801	WO 2002-US2538		20020125
	WO 2002059080	A3	20021219			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-263703P	P	20010125
				US 2001-291965P	P	20010521
	CA 2435829	AA	20020801	CA 2002-2435829		20020125
				US 2001-263703P	P	20010125
				US 2001-291965P	P	20010521
				WO 2002-US2538	W	20020125
	US 2002165275	A1	20021107	US 2002-57203		20020125
	US 6656971	B2	20031202			
				US 2001-263703P	P	20010125
				US 2001-291365P	P	20010517
	EP 1360173	A2	20031112	EP 2002-706049		20020125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2001-263703P	P	20010125
				US 2001-291965P	P	20010521
				WO 2002-US2538	W	20020125
	JP 2004532187	T2	20041021	JP 2002-559382		20020125
				US 2001-263703P	P	20010125
				US 2001-291965P	P	20010521
				WO 2002-US2538	W	20020125
	US 2004157919	A1	20040812	US 2003-713566		20031114
				US 2002-57203	A3	20020125

OS MARPAT 137:124993
IT **444343-09-3P 444343-19-5P 444343-20-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(trisubstituted carbocyclic cyclophilin binding compds.)
RN 444343-09-3 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-[(3,4-dichlorophenyl)methoxy]-N,N'-bis(3,4,5-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 444343-19-5 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-(2-naphthalenylmethoxy)-N,N'-bis[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 444343-20-8 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis(3,4-dichlorophenyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **444342-99-8P 444343-14-0P 444343-15-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(trisubstituted carbocyclic cyclophilin binding compds.)

RN 444342-99-8 CAPLUS
CN 1,3-Benzenedicarboxamide, 5-[(2'-cyano[1,1'-biphenyl]-4-yl)methoxy]-N,N'-bis(3-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 444343-14-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis[4-chloro-3-(trifluoromethyl)phenyl]-5-[[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 444343-15-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N,N'-bis(3,4-dichlorophenyl)-5-[[3-[[(3,4-

dichlorophenyl)amino]carbonyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 18:18:42 ON 11 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 18:18:50 ON 11 MAY 2005
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          156 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 18:19:32 ON 11 MAY 2005
L4           69 S L3
L5            0 S L4 AND NEUROLOG?
L6            0 S L4 AND NEURO?
L7            0 S L4 AND CNS
L8            1 S L4 AND NERV?

=> s l4 and diseases
        209355 DISEASES
             1 DISEASESES
        209356 DISEASES
                  (DISEASES OR DISEASESES)
L9            0 L4 AND DISEASES

=> s l4 and disease
        763217 DISEASE
        209355 DISEASES
        860115 DISEASE
                  (DISEASE OR DISEASES)
L10           1 L4 AND DISEASE

=> s l10 not l8
L11           0 L10 NOT L8
```

5/11/05

```
=> s l4 and use
       1762774 USE
       3022742 USES
       4487998 USE
                 (USE OR USES)
L12          17 L4 AND USE

=> d abs bib fhitstr 1-17
```